SLC35A2, solute carrier family 35 member A2, 7355

N. diseases: 197; N. variants: 18
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE UGT1 and UGT2 enzymes have important roles in pharmacology and toxicology including contributing to interindividual differences in drug disposition as well as to cancer risk. 30724669 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 GeneticVariation group BEFREE Neutropenia is a life-threatening side effect of irinotecan, and UDP glucuronosyltransferases (UGTs) gene polymorphisms could predict the side effects in cancer patients and then reduce IRI-induced toxicity by preventative treatment or a decrease in dose. 28585035 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 GeneticVariation group BEFREE Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. 26828111 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 AlteredExpression group BEFREE Class 1 UGT enzyme expression was also downregulated in cancer SCs and during progression to metastatic castration-resistant prostate cancer (CRPC). 23880823 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 GeneticVariation group BEFREE In summary, this review focuses on the role of the human UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk. 16550166 2006